Vaxcyte, Inc. (PCVX) stock

PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$64.69−3.93 (-5.73%)

Close on Nov 12, 2026Market cap $9.63BP/E –Yield 0.00%

Vaxcyte price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vaxcyte has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?